Investing
EWTX Stock Rises 4.3% on Q3 Results and EDG-7500 Progress
Edgewise Therapeutics shares rose 4.3% after Q3 results showed a $1.17 billion profit from the sevasemten sale and a Phase 3 EDG-7500 trial on track.
Edgewise Therapeutics (EWTX) stock was up 4.3% in regular trading on November 5, 2026, the day after the company reported third quarter results. Cash, cash equivalents and marketable securities reached $1,743.9 million on September 30, 2026, up from $530.1 million at the end of 2025.
What Edgewise Therapeutics reported
| Metric | This period | A year earlier | Change |
|---|---|---|---|
| R&D expenses | $31.6M | $37.5M | Down 16% |
| G&A expenses | $14.6M | $9.4M | Up 55% |
| Interest income | $16.5M | $6.2M | Up 166% |
| Net income (loss) | $1,166.2M | ($40.7M) | Swung to profit |
| Diluted EPS | $9.65 | ($0.39) | Swung to profit |
Diluted EPS is profit per share, counting shares that options and similar awards could add. The profit is a one-off. It comes from a $1.348 billion gain on selling the sevasemten program and muscular dystrophy business to Servier in July 2026, which brought in $1.396 billion of upfront cash. Income tax expense on the deal was $155.3 million. The company still has no revenue from product sales.
R&D (research and development) spending fell mainly because sevasemten costs stopped after the sale. Spending on EDG-7500 and early-stage research went up. G&A (general and administrative) costs rose on hiring, stock-based pay and professional fees.
Why the stock rose 4.3%
The rise was close to twice the size of a typical day's swing for the stock. The company said the Phase 3 trial of EDG-7500 is on track to start by year-end 2026. Phase 3 is the large, late-stage test usually needed for approval. The trial covers both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM), a thickening of the heart muscle. The company also dosed the first patient in its Phase 2 EQUINOX-HFpEF trial of a second drug, EDG-15400.
What to watch next
-
Whether the EDG-7500 Phase 3 trial actually starts by the end of 2026
-
Enrollment updates from the EQUINOX-HFpEF trial
-
Next quarterly report for updated cash and spending levels
FAQ
What is EDG-7500?
It is an experimental oral pill designed to act on the heart muscle's regulatory light chain, slowing early contraction and improving the heart's ability to relax. Positive 12-week Phase 2 results from the CIRRUS-HCM trial were presented at the European Society of Cardiology Congress in August 2026.
What is EDG-15400 being tested for?
It is being tested in adults with heart failure with preserved ejection fraction (HFpEF), meaning the heart pumps normally (ejection fraction of at least 50%) but relaxes poorly. The trial is listed on ClinicalTrials.gov as NCT07795814.
Sources
This article is for information only and is not investment advice.